Vyome Secures $5.3M for VT-1953 Phase 3 Trials via ATM Facility — Vyome Holdings, Inc. (Vyome Therapeutics)

Event summary

Vyome raised $5.3M on January 27, 2026, by selling 1.09M shares at $5.00 each, a 59.2% premium over the prior day's close.
The funding covers VT-1953 Phase 3 interim results expected in mid-2027, with total dilution at ~15% for existing shareholders.
As of January 29, 2026, Vyome had $9.5M in cash, rejecting higher-dilution funding offers from multiple investment banks.
VT-1953, targeting Malignant Fungating Wounds, is estimated to be worth $1B upon Phase 3 completion, per an independent valuation.

The big picture

Vyome's strategic move to secure funding via an ATM facility at minimal dilution underscores its focus on shareholder value amid a competitive biotech landscape. The $1B valuation estimate for VT-1953 highlights the potential upside in addressing Malignant Fungating Wounds, a niche but critical area in immuno-inflammatory conditions. The rejection of higher-dilution offers suggests confidence in the asset's near-term milestones.

What we're watching

Execution Risk: Whether Vyome can deliver Phase 3 interim results on schedule and meet the $1B valuation milestone.
Capital Strategy: How Vyome balances further funding needs without excessive dilution ahead of potential commercialization.
Market Dynamics: The pace at which VT-1953 gains traction in the immuno-inflammatory space, given competitive pressures.